The Global Actemra Market is estimated to be valued at in 2025 and is expected to reach by 2032, declining at a compound annual growth rate from 2025 to 2032.
The global Actemra market has faced a slowdown in recent years, marked by a negative compound annual growth rate (CAGR). While the treatment remains effective in managing autoimmune disorders like rheumatoid arthritis and giant cell arteritis, several challenges have hindered market growth. High treatment costs, potential side effects, and the availability of alternative therapies have limited the demand for Actemra. The entry of biosimilars and the expiration of patents further intensified competition, slowing the market's expansion. These factors combined have contributed to a decline in market growth, resulting in limited prospects for significant expansion in the near term.
The market still presents some opportunities for recovery, primarily through the growing focus on personalized medicine and expanding research that could uncover new therapeutic indications for Actemra. Emerging markets remain a potential growth area, but the overall market trajectory is likely to remain subdued, with limited prospects for significant expansion due to pricing pressures and the increasing presence of biosimilars.
- This report provides in-depth analysis of the global Actemra market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Actemra market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Genentech (Part of Roche)and Chugai Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Actemra market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Actemra market
-
- Rheumatoid Arthritis
- Giant Cell Arteritis (GCA)
- Polyarticular Juvenile Idiopathic Arthritis (PJIA)
- Systemic Juvenile Idiopathic Arthritis (SJIA)
- Cytokine Release Syndrome (CRS)
- Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
-
- 80 mg/4 mL (20 mg/mL)
- 200 mg/10 mL (20 mg/mL)
- 400 mg/20 mL (20 mg/mL)
- 162 mg/0.9 mL for Injection
-
- Single-dose vials
- Single-dose prefilled syringe or autoinjector
-
-
- Adult
- Pediatric
- Geriatric
-
-
- Hospitals
- Specialized Infusion Centers
- Others (Academics and Research Institutes, etc.)
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Genentech (Part of Roche)
- Chugai Pharmaceutical Co., Ltd.
